ID   KPCT_HUMAN              Reviewed;         706 AA.
AC   Q04759; B4DF52; Q14DH6; Q3MJF1; Q64FY5; Q9H508; Q9H549;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   27-MAR-2002, sequence version 3.
DT   10-MAY-2017, entry version 196.
DE   RecName: Full=Protein kinase C theta type;
DE            EC=2.7.11.13;
DE   AltName: Full=nPKC-theta;
GN   Name=PRKCQ; Synonyms=PRKCT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANT LEU-330.
RX   PubMed=7686153;
RA   Chang J.D., Xu Y., Raychowdhury M.K., Ware J.A.;
RT   "Molecular cloning and expression of a cDNA encoding a novel isoenzyme
RT   of protein kinase C (nPKC). A new member of the nPKC family expressed
RT   in skeletal muscle, megakaryoblastic cells, and platelets.";
RL   J. Biol. Chem. 268:14208-14214(1993).
RN   [2]
RP   ERRATUM, AND SEQUENCE REVISION.
RX   PubMed=7983077;
RA   Chang J.D., Xu Y., Raychowdhury M.K., Ware J.A.;
RL   J. Biol. Chem. 269:31322-31322(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Blood;
RX   PubMed=8444877;
RA   Baier G., Telford D., Giampa L., Coggeshall K.M., Baier-Bitterlich G.,
RA   Isakov N., Altman A.;
RT   "Molecular cloning and characterization of PKC theta, a novel member
RT   of the protein kinase C (PKC) gene family expressed predominantly in
RT   hematopoietic cells.";
RL   J. Biol. Chem. 268:4997-5004(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT LEU-330.
RA   Li H., Ke R., Zhou G., Shen C., Zhong G., Lin L., Yang S.;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION IN ACTIVATION OF JUN.
RX   PubMed=8657160; DOI=10.1128/MCB.16.4.1842;
RA   Baier-Bitterlich G., Uberall F., Bauer B., Fresser F., Wachter H.,
RA   Grunicke H., Utermann G., Altman A., Baier G.;
RT   "Protein kinase C-theta isoenzyme selective stimulation of the
RT   transcription factor complex AP-1 in T lymphocytes.";
RL   Mol. Cell. Biol. 16:1842-1850(1996).
RN   [9]
RP   INTERACTION WITH GLRX3.
RX   PubMed=10636891; DOI=10.1074/jbc.275.3.1902;
RA   Witte S., Villalba M., Bi K., Liu Y., Isakov N., Altman A.;
RT   "Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways
RT   by PICOT, a novel protein kinase C-interacting protein with a
RT   thioredoxin homology domain.";
RL   J. Biol. Chem. 275:1902-1909(2000).
RN   [10]
RP   PHOSPHORYLATION AT TYR-90, AND MUTAGENESIS OF TYR-90; ALA-148 AND
RP   LYS-409.
RX   PubMed=10652356; DOI=10.1074/jbc.275.5.3603;
RA   Liu Y., Witte S., Liu Y.C., Doyle M., Elly C., Altman A.;
RT   "Regulation of protein kinase Ctheta function during T cell activation
RT   by Lck-mediated tyrosine phosphorylation.";
RL   J. Biol. Chem. 275:3603-3609(2000).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF BAD.
RX   PubMed=11342610; DOI=10.4049/jimmunol.166.10.5955;
RA   Villalba M., Bushway P., Altman A.;
RT   "Protein kinase C-theta mediates a selective T cell survival signal
RT   via phosphorylation of BAD.";
RL   J. Immunol. 166:5955-5963(2001).
RN   [12]
RP   PHOSPHORYLATION AT THR-538; SER-676 AND SER-695, AND MUTAGENESIS OF
RP   THR-538 AND SER-695.
RX   PubMed=11772397;
RA   Liu Y., Graham C., Li A., Fisher R.J., Shaw S.;
RT   "Phosphorylation of the protein kinase C-theta activation loop and
RT   hydrophobic motif regulates its kinase activity, but only activation
RT   loop phosphorylation is critical to in vivo nuclear-factor-kappaB
RT   induction.";
RL   Biochem. J. 361:255-265(2002).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF STK39/SPAK.
RX   PubMed=14988727; DOI=10.1038/sj.emboj.7600125;
RA   Li Y., Hu J., Vita R., Sun B., Tabata H., Altman A.;
RT   "SPAK kinase is a substrate and target of PKCtheta in T-cell receptor-
RT   induced AP-1 activation pathway.";
RL   EMBO J. 23:1112-1122(2004).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF IRS1.
RX   PubMed=15364919; DOI=10.1074/jbc.C400186200;
RA   Li Y., Soos T.J., Li X., Wu J., Degennaro M., Sun X., Littman D.R.,
RA   Birnbaum M.J., Polakiewicz R.D.;
RT   "Protein kinase C Theta inhibits insulin signaling by phosphorylating
RT   IRS1 at Ser(1101).";
RL   J. Biol. Chem. 279:45304-45307(2004).
RN   [15]
RP   INTERACTION WITH ECT2.
RX   PubMed=15254234; DOI=10.1128/MCB.24.15.6665-6675.2004;
RA   Liu X.F., Ishida H., Raziuddin R., Miki T.;
RT   "Nucleotide exchange factor ECT2 interacts with the polarity protein
RT   complex Par6/Par3/protein kinase Czeta (PKCzeta) and regulates PKCzeta
RT   activity.";
RL   Mol. Cell. Biol. 24:6665-6675(2004).
RN   [16]
RP   FUNCTION, PHOSPHORYLATION AT THR-219; THR-538; SER-676 AND SER-695,
RP   AND MUTAGENESIS OF THR-219; THR-538; SER-676 AND SER-695.
RX   PubMed=16252004; DOI=10.1038/sj.emboj.7600856;
RA   Thuille N., Heit I., Fresser F., Krumbock N., Bauer B.,
RA   Leuthaeusser S., Dammeier S., Graham C., Copeland T.D., Shaw S.,
RA   Baier G.;
RT   "Critical role of novel Thr-219 autophosphorylation for the cellular
RT   function of PKCtheta in T lymphocytes.";
RL   EMBO J. 24:3869-3880(2005).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF CARD11, AND SUBUNIT.
RX   PubMed=16356855; DOI=10.1016/j.immuni.2005.09.014;
RA   Sommer K., Guo B., Pomerantz J.L., Bandaranayake A.D.,
RA   Moreno-Garcia M.E., Ovechkina Y.L., Rawlings D.J.;
RT   "Phosphorylation of the CARMA1 linker controls NF-kappaB activation.";
RL   Immunity 23:561-574(2005).
RN   [18]
RP   FUNCTION IN ACTIVATION OF BCL-X(L)/BCL2L1.
RX   PubMed=16709830; DOI=10.4049/jimmunol.176.11.6709;
RA   Manicassamy S., Gupta S., Huang Z., Sun Z.;
RT   "Protein kinase C-theta-mediated signals enhance CD4+ T cell survival
RT   by up-regulating Bcl-xL.";
RL   J. Immunol. 176:6709-6716(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-348; SER-685 AND
RP   SER-695, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-676 AND SER-695, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF CBLB.
RX   PubMed=19549985; DOI=10.1126/scisignal.2000046;
RA   Gruber T., Hermann-Kleiter N., Hinterleitner R., Fresser F.,
RA   Schneider R., Gastl G., Penninger J.M., Baier G.;
RT   "PKC-theta modulates the strength of T cell responses by targeting
RT   Cbl-b for ubiquitination and degradation.";
RL   Sci. Signal. 2:RA30-RA30(2009).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=11861617; DOI=10.1146/annurev.immunol.20.100301.064807;
RA   Isakov N., Altman A.;
RT   "Protein kinase C(theta) in T cell activation.";
RL   Annu. Rev. Immunol. 20:761-794(2002).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=12473184; DOI=10.1093/oxfordjournals.jbchem.a003295;
RA   Altman A., Villalba M.;
RT   "Protein kinase C-theta (PKC theta): a key enzyme in T cell life and
RT   death.";
RL   J. Biochem. 132:841-846(2002).
RN   [24]
RP   REVIEW.
RX   PubMed=15282562; DOI=10.1038/ni1097;
RA   Spitaler M., Cantrell D.A.;
RT   "Protein kinase C and beyond.";
RL   Nat. Immunol. 5:785-790(2004).
RN   [25]
RP   REVIEW ON FUNCTION.
RX   PubMed=16978534;
RA   Manicassamy S., Gupta S., Sun Z.;
RT   "Selective function of PKC-theta in T cells.";
RL   Cell. Mol. Immunol. 3:263-270(2006).
RN   [26]
RP   REVIEW ON FUNCTION.
RX   PubMed=17544292; DOI=10.1016/j.phrs.2007.04.009;
RA   Hayashi K., Altman A.;
RT   "Protein kinase C theta (PKCtheta): a key player in T cell life and
RT   death.";
RL   Pharmacol. Res. 55:537-544(2007).
RN   [27]
RP   REVIEW ON FUNCTION.
RX   PubMed=18328786; DOI=10.1016/j.it.2008.01.005;
RA   Marsland B.J., Kopf M.;
RT   "T-cell fate and function: PKC-theta and beyond.";
RL   Trends Immunol. 29:179-185(2008).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-685, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   REVIEW ON FUNCTION IN PLATELET ACTIVATION.
RX   PubMed=21944869; DOI=10.1016/j.febslet.2011.09.014;
RA   Cohen S., Braiman A., Shubinsky G., Isakov N.;
RT   "Protein kinase C-theta in platelet activation.";
RL   FEBS Lett. 585:3208-3215(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-685 AND SER-695, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-676; SER-685 AND
RP   SER-695, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-695, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 362-706, AND PHOSPHORYLATION
RP   AT THR-538 AND SER-695.
RX   PubMed=15364937; DOI=10.1074/jbc.M409216200;
RA   Xu Z.B., Chaudhary D., Olland S., Wolfrom S., Czerwinski R.,
RA   Malakian K., Lin L., Stahl M.L., Joseph-McCarthy D., Benander C.,
RA   Fitz L., Greco R., Somers W.S., Mosyak L.;
RT   "Catalytic domain crystal structure of protein kinase C-theta
RT   (PKCtheta).";
RL   J. Biol. Chem. 279:50401-50409(2004).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 361-706, AND PHOSPHORYLATION
RP   AT SER-676 AND SER-695.
RA   Stark W., Bitsch F., Berner A., Buelens F., Graff P., Depersin H.,
RA   Fendrich G., Geiser M., Knecht R., Rahuel J., Rummel G.,
RA   Schlaeppi J.M., Schmitz R., Strauss A., Wagner J.;
RT   "The crystal structure of the kinase domain of the protein kinase C
RT   theta in complex with Nvp-Xaa228.";
RL   Submitted (JAN-2007) to the PDB data bank.
RN   [36]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-240; VAL-306; LEU-330 AND ASN-354.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium-independent, phospholipid- and diacylglycerol
CC       (DAG)-dependent serine/threonine-protein kinase that mediates non-
CC       redundant functions in T-cell receptor (TCR) signaling, including
CC       T-cells activation, proliferation, differentiation and survival,
CC       by mediating activation of multiple transcription factors such as
CC       NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated
CC       T-cells, is required for the activation of NF-kappa-B and JUN,
CC       which in turn are essential for IL2 production, and participates
CC       in the calcium-dependent NFATC1 and NFATC2 transactivation.
CC       Mediates the activation of the canonical NF-kappa-B pathway
CC       (NFKB1) by direct phosphorylation of CARD11 on several serine
CC       residues, inducing CARD11 association with lipid rafts and
CC       recruitment of the BCL10-MALT1 complex, which then activates IKK
CC       complex, resulting in nuclear translocation and activation of
CC       NFKB1. May also play an indirect role in activation of the non-
CC       canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway
CC       leading to JUN activation, acts by phosphorylating the mediator
CC       STK39/SPAK and may not act through MAP kinases signaling. Plays a
CC       critical role in TCR/CD28-induced NFATC1 and NFATC2
CC       transactivation by participating in the regulation of reduced
CC       inositol 1,4,5-trisphosphate generation and intracellular calcium
CC       mobilization. After costimulation of T-cells through CD28 can
CC       phosphorylate CBLB and is required for the ubiquitination and
CC       subsequent degradation of CBLB, which is a prerequisite for the
CC       activation of TCR. During T-cells differentiation, plays an
CC       important role in the development of T-helper 2 (Th2) cells
CC       following immune and inflammatory responses, and, in the
CC       development of inflammatory autoimmune diseases, is necessary for
CC       the activation of IL17-producing Th17 cells. May play a minor role
CC       in Th1 response. Upon TCR stimulation, mediates T-cell protective
CC       survival signal by phosphorylating BAD, thus protecting T-cells
CC       from BAD-induced apoptosis, and by up-regulating BCL-X(L)/BCL2L1
CC       levels through NF-kappa-B and JUN pathways. In platelets,
CC       regulates signal transduction downstream of the ITGA2B, CD36/GP4,
CC       F2R/PAR1 and F2RL3/PAR4 receptors, playing a positive role in
CC       'outside-in' signaling and granule secretion signal transduction.
CC       May relay signals from the activated ITGA2B receptor by regulating
CC       the uncoupling of WASP and WIPF1, thereby permitting the
CC       regulation of actin filament nucleation and branching activity of
CC       the Arp2/3 complex. May mediate inhibitory effects of free fatty
CC       acids on insulin signaling by phosphorylating IRS1, which in turn
CC       blocks IRS1 tyrosine phosphorylation and downstream activation of
CC       the PI3K/AKT pathway. Phosphorylates MSN (moesin) in the presence
CC       of phosphatidylglycerol or phosphatidylinositol. Phosphorylates
CC       PDPK1 at 'Ser-504' and 'Ser-532' and negatively regulates its
CC       ability to phosphorylate PKB/AKT1. {ECO:0000269|PubMed:11342610,
CC       ECO:0000269|PubMed:14988727, ECO:0000269|PubMed:15364919,
CC       ECO:0000269|PubMed:16252004, ECO:0000269|PubMed:16356855,
CC       ECO:0000269|PubMed:16709830, ECO:0000269|PubMed:19549985,
CC       ECO:0000269|PubMed:8657160}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) are
CC       calcium-insensitive, but activated by diacylglycerol (DAG) and
CC       phosphatidylserine. Three specific sites; Thr-538 (activation loop
CC       of the kinase domain), Ser-676 (turn motif) and Ser-695
CC       (hydrophobic region), need to be phosphorylated for its full
CC       activation.
CC   -!- SUBUNIT: Interacts with GLRX3 (via N-terminus). Interacts with
CC       ECT2. Part of a lipid raft complex composed at least of BCL10,
CC       CARD11, MALT1 and IKBKB. {ECO:0000269|PubMed:10636891,
CC       ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:16356855}.
CC   -!- INTERACTION:
CC       Q06187:BTK; NbExp=2; IntAct=EBI-374762, EBI-624835;
CC       P06241:FYN; NbExp=7; IntAct=EBI-374762, EBI-515315;
CC       O76003:GLRX3; NbExp=5; IntAct=EBI-374762, EBI-374781;
CC       Q00613:HSF1; NbExp=2; IntAct=EBI-374762, EBI-719620;
CC       P35570:Irs1 (xeno); NbExp=2; IntAct=EBI-374762, EBI-520230;
CC       P06239:LCK; NbExp=2; IntAct=EBI-374762, EBI-1348;
CC       Q8IVH8:MAP4K3; NbExp=4; IntAct=EBI-374762, EBI-1758170;
CC       Q05513:PRKCZ; NbExp=3; IntAct=EBI-374762, EBI-295351;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Peripheral
CC       membrane protein. Note=In resting T-cells, mostly localized in
CC       cytoplasm. In response to TCR stimulation, associates with lipid
CC       rafts and then localizes in the immunological synapse.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q04759-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q04759-2; Sequence=VSP_017294;
CC       Name=3;
CC         IsoId=Q04759-3; Sequence=VSP_054550;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in skeletal muscle, T-cells,
CC       megakaryoblastic cells and platelets.
CC       {ECO:0000269|PubMed:7686153}.
CC   -!- DOMAIN: The C1 domain, containing the phorbol ester/DAG-type
CC       region 1 (C1A) and 2 (C1B), is the diacylglycerol sensor and the
CC       C2 domain is a non-calcium binding domain.
CC   -!- PTM: Autophosphorylation at Thr-219 is required for targeting to
CC       the TCR and cellular function of PRKCQ upon antigen receptor
CC       ligation. Following TCR stimulation, phosphorylated at Tyr-90 and
CC       Ser-685. {ECO:0000269|PubMed:10652356,
CC       ECO:0000269|PubMed:11772397, ECO:0000269|PubMed:15364937,
CC       ECO:0000269|PubMed:16252004, ECO:0000269|Ref.35}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L01087; AAA75571.1; -; mRNA.
DR   EMBL; L07032; AAA60101.1; -; mRNA.
DR   EMBL; AY702977; AAU29340.1; -; mRNA.
DR   EMBL; AK293935; BAG57313.1; -; mRNA.
DR   EMBL; AL158043; CAC12904.2; -; Genomic_DNA.
DR   EMBL; AL137145; CAC10200.2; -; Genomic_DNA.
DR   EMBL; BC101465; AAI01466.1; -; mRNA.
DR   EMBL; BC113359; AAI13360.1; -; mRNA.
DR   CCDS; CCDS55701.1; -. [Q04759-2]
DR   CCDS; CCDS60482.1; -. [Q04759-3]
DR   CCDS; CCDS7079.1; -. [Q04759-1]
DR   PIR; A45416; A45416.
DR   RefSeq; NP_001229342.1; NM_001242413.2. [Q04759-2]
DR   RefSeq; NP_001269573.1; NM_001282644.1.
DR   RefSeq; NP_001269574.1; NM_001282645.1. [Q04759-3]
DR   RefSeq; NP_001310194.1; NM_001323265.1. [Q04759-1]
DR   RefSeq; NP_001310195.1; NM_001323266.1. [Q04759-3]
DR   RefSeq; NP_006248.1; NM_006257.4. [Q04759-1]
DR   RefSeq; XP_006717528.1; XM_006717465.3. [Q04759-1]
DR   RefSeq; XP_016871899.1; XM_017016410.1. [Q04759-1]
DR   RefSeq; XP_016871900.1; XM_017016411.1. [Q04759-3]
DR   UniGene; Hs.498570; -.
DR   PDB; 1XJD; X-ray; 2.00 A; A=362-706.
DR   PDB; 2ENJ; NMR; -; A=1-125.
DR   PDB; 2ENN; NMR; -; A=144-213.
DR   PDB; 2ENZ; NMR; -; A=227-284.
DR   PDB; 2JED; X-ray; 2.32 A; A/B=361-706.
DR   PDB; 4Q9Z; X-ray; 2.60 A; A/B=374-706.
DR   PDB; 4RA5; X-ray; 2.61 A; A/B=374-706.
DR   PDB; 5F9E; X-ray; 2.00 A; A/B=361-706.
DR   PDBsum; 1XJD; -.
DR   PDBsum; 2ENJ; -.
DR   PDBsum; 2ENN; -.
DR   PDBsum; 2ENZ; -.
DR   PDBsum; 2JED; -.
DR   PDBsum; 4Q9Z; -.
DR   PDBsum; 4RA5; -.
DR   PDBsum; 5F9E; -.
DR   ProteinModelPortal; Q04759; -.
DR   SMR; Q04759; -.
DR   BioGrid; 111574; 30.
DR   IntAct; Q04759; 19.
DR   MINT; MINT-4649766; -.
DR   STRING; 9606.ENSP00000263125; -.
DR   BindingDB; Q04759; -.
DR   ChEMBL; CHEMBL3920; -.
DR   DrugBank; DB04522; Phosphonoserine.
DR   DrugBank; DB02482; Phosphonothreonine.
DR   DrugBank; DB02010; Staurosporine.
DR   DrugBank; DB00675; Tamoxifen.
DR   GuidetoPHARMACOLOGY; 1488; -.
DR   iPTMnet; Q04759; -.
DR   PhosphoSitePlus; Q04759; -.
DR   BioMuta; PRKCQ; -.
DR   DMDM; 20141582; -.
DR   EPD; Q04759; -.
DR   MaxQB; Q04759; -.
DR   PaxDb; Q04759; -.
DR   PeptideAtlas; Q04759; -.
DR   PRIDE; Q04759; -.
DR   DNASU; 5588; -.
DR   Ensembl; ENST00000263125; ENSP00000263125; ENSG00000065675. [Q04759-1]
DR   Ensembl; ENST00000397176; ENSP00000380361; ENSG00000065675. [Q04759-2]
DR   Ensembl; ENST00000539722; ENSP00000441752; ENSG00000065675. [Q04759-3]
DR   GeneID; 5588; -.
DR   KEGG; hsa:5588; -.
DR   UCSC; uc001ijj.3; human. [Q04759-1]
DR   CTD; 5588; -.
DR   DisGeNET; 5588; -.
DR   GeneCards; PRKCQ; -.
DR   HGNC; HGNC:9410; PRKCQ.
DR   HPA; HPA065279; -.
DR   HPA; HPA073098; -.
DR   MIM; 600448; gene.
DR   neXtProt; NX_Q04759; -.
DR   OpenTargets; ENSG00000065675; -.
DR   PharmGKB; PA33773; -.
DR   eggNOG; KOG0694; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00820000126964; -.
DR   HOGENOM; HOG000233022; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; Q04759; -.
DR   KO; K18052; -.
DR   OMA; REPQGIS; -.
DR   OrthoDB; EOG091G0QRS; -.
DR   PhylomeDB; Q04759; -.
DR   TreeFam; TF102004; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins.
DR   Reactome; R-HSA-114508; Effects of PIP2 hydrolysis.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade.
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-373752; Netrin-1 signaling.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   SABIO-RK; Q04759; -.
DR   SignaLink; Q04759; -.
DR   SIGNOR; Q04759; -.
DR   ChiTaRS; PRKCQ; human.
DR   EvolutionaryTrace; Q04759; -.
DR   GeneWiki; PRKCQ; -.
DR   GenomeRNAi; 5588; -.
DR   PMAP-CutDB; Q04759; -.
DR   PRO; PR:Q04759; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000065675; -.
DR   CleanEx; HS_PRKCQ; -.
DR   ExpressionAtlas; Q04759; baseline and differential.
DR   Genevisible; Q04759; HS.
DR   GO; GO:0016235; C:aggresome; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0001772; C:immunological synapse; IEA:Ensembl.
DR   GO; GO:0005622; C:intracellular; IBA:GO_Central.
DR   GO; GO:0005815; C:microtubule organizing center; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; TAS:Reactome.
DR   GO; GO:0004697; F:protein kinase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0097194; P:execution phase of apoptosis; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0006509; P:membrane protein ectodomain proteolysis; ISS:BHF-UCL.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0070233; P:negative regulation of T cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0032740; P:positive regulation of interleukin-17 production; ISS:UniProtKB.
DR   GO; GO:0045086; P:positive regulation of interleukin-2 biosynthetic process; IEA:Ensembl.
DR   GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0050870; P:positive regulation of T cell activation; ISS:UniProtKB.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:2000318; P:positive regulation of T-helper 17 type immune response; ISS:UniProtKB.
DR   GO; GO:2000570; P:positive regulation of T-helper 2 cell activation; ISS:UniProtKB.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IMP:BHF-UCL.
DR   GO; GO:1904355; P:positive regulation of telomere capping; IMP:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0001558; P:regulation of cell growth; NAS:UniProtKB.
DR   GO; GO:0090330; P:regulation of platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   CDD; cd00029; C1; 2.
DR   CDD; cd05619; STKc_nPKC_theta; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR034668; nPKC_theta.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR027264; PKC_theta.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR014376; Prot_kin_PKC_delta.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000551; PKC_delta; 1.
DR   PIRSF; PIRSF501105; Protein_kin_C_theta; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Immunity; Inflammatory response; Kinase;
KW   Magnesium; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN         1    706       Protein kinase C theta type.
FT                                /FTId=PRO_0000055708.
FT   DOMAIN        8    123       C2.
FT   DOMAIN      380    634       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      635    706       AGC-kinase C-terminal.
FT   ZN_FING     159    209       Phorbol-ester/DAG-type 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   ZN_FING     231    281       Phorbol-ester/DAG-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     386    394       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    504    504       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     409    409       ATP.
FT   MOD_RES      90     90       Phosphotyrosine; by LCK.
FT                                {ECO:0000269|PubMed:10652356}.
FT   MOD_RES     219    219       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16252004}.
FT   MOD_RES     348    348       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     538    538       Phosphothreonine; by PDPK1.
FT                                {ECO:0000305|PubMed:11772397,
FT                                ECO:0000305|PubMed:15364937,
FT                                ECO:0000305|PubMed:16252004}.
FT   MOD_RES     676    676       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:11772397,
FT                                ECO:0000269|PubMed:16252004,
FT                                ECO:0000269|Ref.35}.
FT   MOD_RES     685    685       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     695    695       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:11772397,
FT                                ECO:0000269|PubMed:15364937,
FT                                ECO:0000269|PubMed:16252004,
FT                                ECO:0000269|Ref.35}.
FT   VAR_SEQ       2    126       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054550.
FT   VAR_SEQ     550    612       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_017294.
FT   VARIANT     240    240       K -> N (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042319.
FT   VARIANT     306    306       D -> V (in dbSNP:rs45590231).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042320.
FT   VARIANT     330    330       P -> L (in dbSNP:rs2236379).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:7686153,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_020401.
FT   VARIANT     354    354       D -> N (in dbSNP:rs34524148).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042321.
FT   MUTAGEN      90     90       Y->F: Loss of function in T-cells
FT                                proliferation. No effect on kinase
FT                                activity. {ECO:0000269|PubMed:10652356}.
FT   MUTAGEN     148    148       A->E: Constitutively active form.
FT                                {ECO:0000269|PubMed:10652356}.
FT   MUTAGEN     219    219       T->A: Loss of transactivation of the IL2
FT                                promoter and translocation to the plasma
FT                                membrane. No effect on kinase activity.
FT                                {ECO:0000269|PubMed:16252004}.
FT   MUTAGEN     409    409       K->A,E: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:10652356}.
FT   MUTAGEN     538    538       T->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:11772397,
FT                                ECO:0000269|PubMed:16252004}.
FT   MUTAGEN     676    676       S->A: Reduction in kinase activity.
FT                                {ECO:0000269|PubMed:16252004}.
FT   MUTAGEN     695    695       S->A: Reduction in kinase activity.
FT                                {ECO:0000269|PubMed:11772397,
FT                                ECO:0000269|PubMed:16252004}.
FT   CONFLICT    700    700       G -> R (in Ref. 1; AAA75571 and 4;
FT                                AAU29340). {ECO:0000305}.
FT   STRAND        5     13       {ECO:0000244|PDB:2ENJ}.
FT   STRAND       28     39       {ECO:0000244|PDB:2ENJ}.
FT   STRAND       42     52       {ECO:0000244|PDB:2ENJ}.
FT   STRAND       56     62       {ECO:0000244|PDB:2ENJ}.
FT   STRAND       69     75       {ECO:0000244|PDB:2ENJ}.
FT   STRAND       83     89       {ECO:0000244|PDB:2ENJ}.
FT   HELIX        90     98       {ECO:0000244|PDB:2ENJ}.
FT   TURN         99    101       {ECO:0000244|PDB:2ENJ}.
FT   STRAND      103    108       {ECO:0000244|PDB:2ENJ}.
FT   STRAND      110    112       {ECO:0000244|PDB:2ENJ}.
FT   STRAND      114    121       {ECO:0000244|PDB:2ENJ}.
FT   STRAND      155    159       {ECO:0000244|PDB:2ENN}.
FT   STRAND      161    165       {ECO:0000244|PDB:2ENN}.
FT   STRAND      174    176       {ECO:0000244|PDB:2ENN}.
FT   STRAND      187    189       {ECO:0000244|PDB:2ENN}.
FT   STRAND      191    193       {ECO:0000244|PDB:2ENN}.
FT   STRAND      196    199       {ECO:0000244|PDB:2ENN}.
FT   HELIX       200    202       {ECO:0000244|PDB:2ENN}.
FT   STRAND      234    236       {ECO:0000244|PDB:2ENZ}.
FT   STRAND      246    248       {ECO:0000244|PDB:2ENZ}.
FT   STRAND      255    257       {ECO:0000244|PDB:2ENZ}.
FT   STRAND      259    265       {ECO:0000244|PDB:2ENZ}.
FT   TURN        271    276       {ECO:0000244|PDB:2ENZ}.
FT   TURN        281    283       {ECO:0000244|PDB:2ENZ}.
FT   HELIX       377    379       {ECO:0000244|PDB:5F9E}.
FT   STRAND      380    388       {ECO:0000244|PDB:1XJD}.
FT   STRAND      390    399       {ECO:0000244|PDB:1XJD}.
FT   TURN        400    402       {ECO:0000244|PDB:1XJD}.
FT   STRAND      405    412       {ECO:0000244|PDB:1XJD}.
FT   HELIX       413    418       {ECO:0000244|PDB:1XJD}.
FT   HELIX       422    435       {ECO:0000244|PDB:1XJD}.
FT   STRAND      444    449       {ECO:0000244|PDB:1XJD}.
FT   STRAND      451    459       {ECO:0000244|PDB:1XJD}.
FT   STRAND      463    465       {ECO:0000244|PDB:5F9E}.
FT   HELIX       466    473       {ECO:0000244|PDB:1XJD}.
FT   HELIX       478    497       {ECO:0000244|PDB:1XJD}.
FT   HELIX       507    509       {ECO:0000244|PDB:1XJD}.
FT   STRAND      510    512       {ECO:0000244|PDB:1XJD}.
FT   STRAND      518    520       {ECO:0000244|PDB:1XJD}.
FT   HELIX       543    545       {ECO:0000244|PDB:1XJD}.
FT   HELIX       548    551       {ECO:0000244|PDB:1XJD}.
FT   HELIX       559    574       {ECO:0000244|PDB:1XJD}.
FT   HELIX       584    593       {ECO:0000244|PDB:1XJD}.
FT   HELIX       604    613       {ECO:0000244|PDB:1XJD}.
FT   HELIX       618    620       {ECO:0000244|PDB:1XJD}.
FT   HELIX       628    630       {ECO:0000244|PDB:1XJD}.
FT   HELIX       632    634       {ECO:0000244|PDB:1XJD}.
FT   HELIX       639    643       {ECO:0000244|PDB:1XJD}.
FT   HELIX       666    669       {ECO:0000244|PDB:5F9E}.
FT   HELIX       680    685       {ECO:0000244|PDB:5F9E}.
FT   TURN        690    693       {ECO:0000244|PDB:1XJD}.
FT   HELIX       699    706       {ECO:0000244|PDB:5F9E}.
SQ   SEQUENCE   706 AA;  81865 MW;  B3C53AB892D5210A CRC64;
     MSPFLRIGLS NFDCGSCQSC QGEAVNPYCA VLVKEYVESE NGQMYIQKKP TMYPPWDSTF
     DAHINKGRVM QIIVKGKNVD LISETTVELY SLAERCRKNN GKTEIWLELK PQGRMLMNAR
     YFLEMSDTKD MNEFETEGFF ALHQRRGAIK QAKVHHVKCH EFTATFFPQP TFCSVCHEFV
     WGLNKQGYQC RQCNAAIHKK CIDKVIAKCT GSAINSRETM FHKERFKIDM PHRFKVYNYK
     SPTFCEHCGT LLWGLARQGL KCDACGMNVH HRCQTKVANL CGINQKLMAE ALAMIESTQQ
     ARCLRDTEQI FREGPVEIGL PCSIKNEARP PCLPTPGKRE PQGISWESPL DEVDKMCHLP
     EPELNKERPS LQIKLKIEDF ILHKMLGKGS FGKVFLAEFK KTNQFFAIKA LKKDVVLMDD
     DVECTMVEKR VLSLAWEHPF LTHMFCTFQT KENLFFVMEY LNGGDLMYHI QSCHKFDLSR
     ATFYAAEIIL GLQFLHSKGI VYRDLKLDNI LLDKDGHIKI ADFGMCKENM LGDAKTNTFC
     GTPDYIAPEI LLGQKYNHSV DWWSFGVLLY EMLIGQSPFH GQDEEELFHS IRMDNPFYPR
     WLEKEAKDLL VKLFVREPEK RLGVRGDIRQ HPLFREINWE ELERKEIDPP FRPKVKSPFD
     CSNFDKEFLN EKPRLSFADR ALINSMDQNM FRNFSFMNPG MERLIS
//
